Prostaglandin E2 modulation and uses thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 1, 2013
Grant Date -
Dec 2, 2010
app pub date -
Jun 16, 2010
filing date -
Sep 11, 2007
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Methods, uses, kits and products are described for the prognosis, diagnosis, prevention and treatment of myotronic dystrophy type 1 (DM1), and more particularly for the prognosis, diagnosis, prevention and treatment of the congenital form of myotronic dystrophy type 1 (cDM1), based on changes in/modulation of prostaglandin E2 (PGE2).
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully